ViroGates A/S announced that the development of the company's new point- of-care product, suPARnostic? POC+, will be delayed to the first half of 2022. suPARnostic? POC+ is co-developed with Austrian-based GENSPEED Biotech GmbH and will enable the measurement of both suPAR and CRP in a blood sample from a fingerprick. The product will expand the addressable market for ViroGates to pre-hospital customers, general practitioners, and others. The product was previously scheduled for launch in the second half of 2021. The product launch is now expected in the first half of 2022, following a clinical validation study and an expected CE-IVD approval. The reason for the delay is related to general analytical performance parameters. The final steps of the product development and manufacturing are pivotal and required from a regulatory point to have completed before a clinical validation study can be initiated.